Ameritas Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ameritas Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	4,842 +66	+1%	+$19.9K	0.04%	507
2026 Q1	$1.58M	Hold	4,776	–	–	0.05%	427
2025 Q4	$1.9M	Buy	+4,776	New	+$2.11M	0.06%	354
2014 Q2	–	Sell	-5,020	Closed	-$337K	–	1090
2014 Q1	$337K	Sell	5,020 -99	-2%	-$7.67K	0.03%	742
2013 Q4	$329K	Buy	5,119 +88	+2%	+$5.25K	0.03%	772
2013 Q3	$322K	Buy	+5,031	New	+$251K	0.03%	709

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameritas Investment Partners's ALNY Position: Q2 2026 in Review

Ameritas Investment Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 1.4% in Q2 2026, buying an estimated $19.9K and bringing the position to 4,842 shares worth $1.46M. The position accounts for 0.04% of the portfolio, ranked #507.

Ameritas Investment Partners first reported a position in ALNY in Q3 2013 and has held it in 6 quarters since. The position peaked at $1.9M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Ameritas Investment Partners held 4,842 shares of Alnylam Pharmaceuticals worth $1.46M as of Q2 2026.
Ameritas Investment Partners bought 66 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $19.9K.
Alnylam Pharmaceuticals made up 0.04% of Ameritas Investment Partners's portfolio in Q2 2026, its #507 holding.
Ameritas Investment Partners first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 6 quarters since.
Ameritas Investment Partners's Alnylam Pharmaceuticals position peaked at $1.9M in Q4 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.